Effects of treatment of diabetic rats with human recombinant nerve growth factor on sciatic nerve conduction, Doppler flux and substance P levels

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 10, Issue 1, 1997, Pages 3-8

  Maeda, K ^a   Fernyhough, P ^a   Tomlinson, D R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin; Nerve blood flow; Nerve conduction; Nerve growth factor; Neuropathy; Substance P

Indexed keywords

HEMOGLOBIN; INSULIN; RECOMBINANT NERVE GROWTH FACTOR; STREPTOZOCIN; SUBSTANCE P;

ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030969540     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jakobsen J., Brimijoin S., Skau K., Sidenius P., Wells D.: Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes 30: 797-803, 1981.
2. 125I] nerve growth factor in ileal mesenteric nerves in vitro: effect of streptozotocin diabetes. Brain Res. 378: 325-336, 1986.
3. Hellweg R., Härtung H.-D.: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. Neurosci. Res. 26: 258-267, 1990.
4. Fernyhough P., Diemel L.T., Brewster W.J., Tomlinson D.R.: Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor mRNA in streptozotocin-diabetic rats; effects of insulin treatment. Neuroscience 62: 337-344, 1994.
5. Diemel L.T., Stevens E.J., Willars G.B., Tomlinson D.R.: Depletion of substance P and calcitonin gene-related peptide in sciatic nerve of rats with experimental diabetes; effects of insulin and aldose reductase inhibition. Neurosci. Lett. 137: 253-256, 1992.
6. Diemel L.T., Brewster W.J., Fernyhough P., Tomlinson D.R.: Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Mol. Brain Res. 21: 171-175, 1994.
7. Eliasson S.G.: Nerve conduction changes in experimental diabetes. J. Clin. Invest. 43: 2353-2358, 1964.
8. Tuck R.R., Schmelzer J.D., Low P.A.: Endoneural blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107: 935-950, 1984.
9. Stevens E.J., Kalichman M.W., Mizisin A.P., Calcutt N.A., Tomlinson D.R.: Blood flow in nerve and dorsal root ganglia in experimental diabetes; effects of insulin. J. Physiol. 475: 68P-1994.
10. Tomlinson D.R., Robinson J.P., Willars G.B., Keen P.: Deficient axonal transport of substance P in streptozocin-induced diabetic rats. Effects of sorbinil and insulin. Diabetes 37: 488-493, 1988.
11. Stevens E.J., Carrington A.L., Tomlinson D.R.: Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia 37: 43-48, 1994.
12. + pump in streptozotocin-diabetic rats. Br. J. Pharmacol. 105: 355-360, 1992.
13. Greene D.A., De Jesus P.V.J., Winegrad A.I.: Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J. Clin. Invest. 55: 1326-1336, 1975.
14. Mayer J.H., Tomlinson D.R.: Axonal transport of cholinergic transmitter enzymes in vagus and sciatic nerves of rats with acute experimental diabetes mellitus; correlation with motor nerve conduction velocity and effects of insulin. Neuroscience 9: 951-957, 1983.
15. Yoshida T., Nishioka H., Yoshioka K., Nakano K., Kondo M., Terashima H.: Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes 36: 6-13, 1987.
16. Robinson J.P., Willars G.B., Tomlinson D.R., Keen P.: Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor 'statil'. Brain Res. 426: 339-348, 1987.
17. Grothe C., Unsicker K.: Neuron-enriched cultures of adult rat dorsal root ganglia: establishment, characterization, survival, and neuropeptide expression in response to trophic factors. J. Neurosci. Res. 18: 539-550, 1987.
18. Lindsay R.M., Harmar A.J.: Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 337: 362-364, 1989.
19. Lindsay R.M., Lockett C., Stemberg J., Winter J.: Neuropeptide expression in cultures of adult sensory neurons: Modulation of substance P and calcitonin gene-related peptide levels by nerve growth factor. Neuroscience 33: 53-65, 1989.
20. Gilchrist C.A., Morrison C.F., Chapman K.E., Harmar A.J.: Identification of nerve growth factor-responsive sequences within the 5′ region of the bovine preprotachykinin gene. DNA Cell Biol. 10: 743-749, 1991.
21. Apfel S.C., Arezzo J.C., Brownlee M., Federoff H., Kessler J.A.: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634: 7-12, 1994.
22. Tomlinson D.R., Holmes P.R., Mayer J.H.: Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus. Neurosci. Lett. 31: 189-193, 1982.
23. Yue D.K., Hanwell M.A., Satchell P.M., Turtle J.R.: The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 31: 789-794, 1982.
24. Kikkawa R., Hatanaka I., Yasuda H., Kobayashi N., Shigeta Y., Terashima H., Morimura T., Tsuboshima M.: Effect of a new aldose reductase inhibitor. (E)-3-carboxymethyl-5-((2E)-methyl-3-phenylpropenylidene)rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 24: 290-292, 1983.
25. Notvest R.R. Inserra J.J.: Tolrestat, an aldose reductase inhibitor, prevents nerve dysfunction in conscious diabetic rats. Diabetes 36: 500-504, 1987.
26. Mizuno K., Kato N., Matsubara A., Nakano K., Kurono M.: Effects of a new aldose reductase inhibitor. (2S, 4S)-6-fluoro-2′, 5′-dioxospiro-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41: 1081-1086, 1992.
27. Cameron N.E., Cotter M.A., Dines K.C., Maxfield E.K., Carey F., Mirrlees D.J.: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37: 651-663, 1994.
28. Low P.A., Tuck R.R., Dyck P.J., Schmelzer J.D., Yao J.K.: Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc. Natl. Acad, Sci. USA 81: 6894-6898, 1984.
29. Low P.A., Schmelzer J.D., Ward K.K., Yao J.K.: Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am. J. Physiol. 250: E94-E99, 1986.
30. Smith W.J., Diemel L.T., Leach R.M., Tomlinson D.R.: Central hypoxaemia in rats provokes neurological defects similar to those seen in experimental diabetes mellitus: Evidence for a partial role of endoneurial hypoxia in diabetic neuropathy. Neuroscience 45: 255-259, 1991.
31. Wong V., Arriaga R., Ip N.Y., Lindsay R.M.: The neurotrophim BDNF, NT-3 and NT-4/5, but not NGF. up-regulate the cholinergic phenotype of developing motor neurons. Eur. J. Neurosci. 5: 466-474, 1993.
32. Van Q., Elliott J.L., Matheson C., Sun J., Zhang L., Mu X., Rex K.L., Snider W.D.: Influences of neurotrophins on mammalian motoneurons in vivo. J. Neurobiol. 24: 1555-1577, 1993.
33. Johnson E.M., Taniuchi M., DiStefano P.S.: Expression and possible function of nerve growth factor receptors on Schwann cells. Trends Neurosci. 11: 299-304, 1988.
34. Yamamoto M., Sobue G., Li M., Arakawa Y., Mitsuma T., Kimata K.: Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and low-affinity nerve growth factor receptor (LNGFR) mRNA levels in cultured rat Schwann cells; Differential time- and dose-dependent regulation by cAMP. Neurosci. Lett. 152: 37-40, 1993.
35. Zettler C., Head R.J., Rush R.A.: Chronic nerve growth factor treatment of normotensive rats. Brain Res. 538: 251-262, 1991.